RCM
BIO icon

Riverhead Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Riverhead Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$888K Hold
2,668
– – 0.03% 524
2019
Q2 		$834K Hold
2,668
– – 0.03% 547
2019
Q1 		$816K Sell
2,668
-500
-16% -$135K 0.03% 523
2018
Q4 		$736K Sell
3,168
-100
-3% -$26.8K 0.03% 531
2018
Q3 		$1.02M Buy
3,268
+1,000
+44% +$310K 0.04% 481
2018
Q2 		$654K Hold
2,268
– – 0.03% 586
2018
Q1 		$567K Hold
2,268
– – 0.02% 608
2017
Q4 		$541K Buy
2,268
+300
+15% +$72.7K 0.02% 630
2017
Q3 		$437K Buy
1,968
+169
+9% +$38K 0.02% 654
2017
Q2 		$407K Buy
1,799
+799
+80% +$174K 0.02% 669
2017
Q1 		$199K Buy
1,000
+100
+11% +$19.3K 0.01% 773
2016
Q4 		$164K Buy
900
+100
+13% +$17K 0.01% 782
2016
Q3 		$131K Sell
800
-828
-51% -$126K 0.01% 804
2016
Q2 		$233K Sell
1,628
-1,998
-55% -$285K 0.01% 831
2016
Q1 		$496K Sell
3,626
-74
-2% -$9.71K 0.01% 884
2015
Q4 		$513K Buy
3,700
+2,800
+311% +$388K 0.01% 884
2015
Q3 		$121K Buy
+900
New +$130K ﹤0.01% 980

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Riverhead Capital Management's BIO Position: Q3 2019 in Review

Riverhead Capital Management held its Bio-Rad Laboratories Class A (BIO) position steady in Q3 2019 at 2,668 shares worth $888K. The position accounts for 0.03% of the portfolio, ranked #524.

Riverhead Capital Management first reported a position in BIO in Q3 2015 and has held it in 17 quarters since. The position peaked at $1.02M in Q3 2018. 355 funds tracked by Wall St. Rank hold BIO as of Q3 2019.

  • Riverhead Capital Management held 2,668 shares of Bio-Rad Laboratories Class A worth $888K as of Q3 2019.
  • Riverhead Capital Management left its Bio-Rad Laboratories Class A share count unchanged in Q3 2019.
  • Bio-Rad Laboratories Class A made up 0.03% of Riverhead Capital Management's portfolio in Q3 2019, its #524 holding.
  • Riverhead Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and has held it in 17 quarters since.
  • Riverhead Capital Management's Bio-Rad Laboratories Class A position peaked at $1.02M in Q3 2018.
  • 355 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.